Pharmaceutical company Nantong Novast Laboratories (SHE:301569) priced its initial public offering on Shenzhen's ChiNext Board of 133.7 million shares at 7.00 yuan apiece to raise about 935.9 million yuan, according to a Thursday filing with the Shenzhen bourse.
Proceeds will fund an industrialization base, drug research and development, and working capital.
China International Capital serves as lead underwriter.